Key clinical point: Many patients receiving tyrosine kinase inhibitors (TKIs) are taking complementary therapies or eating foods that interfere with TKI metabolism.
Major finding: More than one-third of patients with chronic myeloid leukemia (34%) reported taking a complementary medicine.
Study details: A survey of 61 patients with chronic myeloid leukemia (CML) who were also taking a TKI.
Disclosures: The investigators reported having no conflicts of interest.
REPORTING FROM BSH 2019
This Week's Must Reads
Must Reads in CML
Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.